Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

NCT00713336 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ZD4054
DRUG: Moxifloxacin
DRUG: ZD4054 Placebo
DRUG: Moxifloxacin placebo
DRUG: ZD4054 Placebo
DRUG: ZD4054
DRUG: ZD4054

Sponsor

AstraZeneca